MedTrace Logo

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology

NCT02127788 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-10-21

No results posted yet for this study

Summary

The purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in French haematological and onco-haematological units. The efficacy and the safety outcomes will be described.

Conditions

  • Antifungal Prophylaxis
  • Haemopathy

Interventions

DRUG

Micafungin

intravenous

Sponsors & Collaborators

  • Astellas Pharma S.A.S.

    lead INDUSTRY

Principal Investigators

  • Medical and Scientific Affairs Manager, Infectious Diseases · Astellas Pharma S.A.S.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-03
Primary Completion
2016-01-27
Completion
2016-01-27

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02127788 on ClinicalTrials.gov